全程化药学服务在免疫检查点抑制剂治疗晚期非小细胞肺癌的应用  

Evaluation of advantages of whole-process pharmaceutical care in treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors

作　　者：徐晶 王学群 胡文弋 Xu Jing;Wang Xue-qun;Hu Wen-yi(Department of Pharmacy,Yingtan 184 Hospital,Yingtan 335000,China;Department of Oncology,Yingtan 184 Hospital,Yingtan 335000,China;Department of Pharmacy,908 Hospital of PLA Joint Logistic Support Force,Nanchang 330002,China)

机构地区：[1]鹰潭一八四医院药学科,鹰潭335000 [2]鹰潭一八四医院肿瘤科,鹰潭335000 [3]中国人民解放军联勤保障部队第九〇八医院药剂科,南昌330002

出　　处：《中国药物应用与监测》2024年第6期858-861,共4页Chinese Journal of Drug Application and Monitoring

基　　金：江西省中医药管理局科技计划项目(2023B1362)。

摘　　要：目的分析全程化药学服务在免疫检查点抑制剂(ICIs)治疗晚期非小细胞肺癌中的应用优势。方法采用前瞻性随机对照研究方法,选择2022年1月至2024年1月鹰潭一八四医院收治的晚期非小细胞肺癌患者合计72例纳入观察对象,所有患者均择机开展ICIs治疗,通过等间隔抽取法将所有患者均分为对照组(n=36)、观察组(n=36),对照组接受临床医生基本常规药物治疗、观察组在对照组的治疗基础上联合全程化药学服务干预,比较患者组间疗效的差异。结果观察组肺癌患者的症状缓解时间短于对照组(3.18±2.15)d vs(4.72±2.54)d,P<0.05;住院时间短于对照组(4.25±0.73)d vs(6.32±0.53)d,P<0.05;舒适度评分有所提高且高于对照组(91.42±2.19)分vs(72.21±2.32)分,P<0.05;治疗期间的并发症发生率低,对照组为25.00%(9/36),观察组为5.56%(2/36),两组比较差异有统计学意义(χ^(2)=5.258,P<0.05)。结论全程化药学服务应用于ICIs治疗晚期非小细胞肺癌患者的效果确切,可缩短患者病程、促进患者康复、保障用药安全、提高患者舒适度。Objective To analyze the advantages of whole-process pharmaceutical care in the treatment of advanced non-small cell lung cancer with immune checkpoint inhibitors.Methods A total of 72 patients with advanced non-small cell lung cancer admitted to Yingtan 184 Hospital from January 2022 to January 2024 were selected as the research subjects to receive immune checkpoint inhibitor treatment.These patients were divided into the control group(n=36)and observation group(n=36)by computer grouping method.The patients in the control group received the routine treatment and nursing while those in the intervention group received the integrated pharmaceutical care in addition to the regimen in the control group.The difference in therapeutic efficacy was compared between the two groups.Results The symptom remission time and hospitalization time were significantly shorter in the observation group than in the control((3.18±2.15)d vs(4.72±2.54)d,(4.25±0.73)d vs(6.32±0.53)d,all P<0.05).The comfort score was significantly higher in the observation group than in the control((91.42±2.19)scores vs(72.21±2.32)scores,P<0.05).The complication rate was 25.00%(9/36)in the control group and 5.56%(2/36)in the observation group and the difference was statistically significant(χ^(2)=5.258,P<0.05).Conclusion The application of whole-process pharmaceutical care in the treatment of advanced non-small cell lung cancer patients with immune checkpoint inhibitors has a definite effect since it can shorten the course of patients’disease,promote patients’rehabilitation,ensure medication safety and improve patients’comfort.Therefore,it is worthy of promotion.

关 键 词：免疫检查点抑制剂 全程化药学服务 并发症 非小细胞肺癌 用药安全 

分 类 号：R734.2[医药卫生—肿瘤]